Dear Sir, In their recent paper Muller et al. [1] have presented a very preliminary evaluation of a potential new PET radioligand for the dopamine transporter, [llC]NNC 12-0722. This is a compound derived from the better known ligands for that site, GBR 12935 and GBR 12909. In their paper, the authors discuss previous efforts to utilize a fluorine-18 analog of these compounds, namely [18F]GBR 13119 (which is fluoroGBR 12935, or desfluoroGBR 12909), and they state "...brain uptake was general and there was no marked accumulation of radioactivity in regions known to have a high density of dopamine transporters" (authors' own words). This statement is grossly erroneous.
We had done extensive evaluation of [18F]GBR 13119, and the closely related compound [~SF]GBR 12909, including studies in rodents, monkeys and man. The monkey PET image published by us (and referenced by the authors) clearly shows bilateral accumulation of the radiotracer, [18F]GBR 13119, in the striatum of the monkey brain [2] . That paper also presents the pharmacokinetic time course for radioactivity in striatum and cerebellum, clearly showing a differential accumulation in the DA transporter-rich striatal tissue. The striatum to cerebellum ratios in monkeys were 1.5-1.7, not that dissimilar than what had been previously reported in monkeys for [l~C]nomifensine, a radioligand also successfully used for primate and human PET imaging of DA transporters. Our publications have documented the pharmacological specificity of the regional in vivo binding of this radiotracer in mammalian brain [2, 3] . Finally, we have already reported human imaging and full pharmacokinetic modelling of [18F]GBR 12909 in human brain [4] .
Certainly some more recent radioligands, such as [I1c]CIT, are better imaging agents but their quantitative value is still being studied.
[HC]NNC 12-0722 might also be a better radioligand, but the authors need to do much work to prove this point. They have not demonstrated in any animal that the in vivo uptake and concentration of radioactivity in the striatum of an animal can be selectively blocked with known, structurally unrelated antagonists of the DA transporter. They have not demonstrated that the in vivo brain distribution cannot be altered by pharmacological treatments with ligands for other receptors or transporters. They have not demonstrated that the uptake in brain is not due to metabolites, which may or may not be binding to the DA transporter.
At least all of these things have been done for [18F]GBR 13119 and [18F]GBR 12909, even if they are not "optimal" imaging agents.
A full evaluation of [llC]NNC 12-0722 is needed and should be pursued. The high brain uptake, and possibly more rapid kinetics, are indeed encouraging. Until these further studies are complete, [llC]NNC 12-0722 is just one of a long list of radioactive compounds, of several pharmacological classes, that will concentrate in the striatum.
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